研讨课程

临床研究中最佳伦理规范的理解与实施

2013年4月9-10日
南京饭店 | 中国 • 南京

为满足更多临床机构专业人员的研讨需求，DIA中国将在南京举办第三届伦理研讨活动。此次课程将在延续上届优势内容的基础上，通过更多国内外实用案例，讲授临床试验中被国际广泛接受与要求的伦理标准。专家将结合临床实例对伦理指南及实施方面的各个环节进行详细阐述。通过课堂练习与案例分析，加强互动，探讨解决问题的最佳途径。

学习内容

- 简介- 生物医学研究伦理发展与赫尔辛基宣言及ICH GCP
- 中国药物临床试验伦理要求
- 临床试验I-IV期（包括上市后观察性研究）受试者的保护
- 确保受试者权益的临床试验伦理审查过程
- 临床试验方案的伦理审查重点
- 正常成年受试者知情同意过程
- 对受试者须知及知情同意过程的审查重点
- 涉及弱势成人群体及儿童的临床试验伦理问题
- 关于伦理问题的案例分析
- 对参加临床试验受试者的支持及经济补偿的伦理考虑
- 临床试验研究完整性、伦理和社会责任

学习目标

- 更好地理解临床研究的伦理要求及影响
- 进一步熟悉GCP，ICH和SFDA新的伦理指导原则
- 遵循法规规范
- 提高临床研究设计能力，确保伦理的有效实施以符合检查和申报要求

会议咨询，请联系:

赵英
电话.+86.10.6260.2242 | 传真.+86.10.6260.2201
电子邮件: dia@diachina.org

谢飞
电话.+86.10.6260.2240 | 传真.+86.10.6260.2201
电子邮件: dia@diachina.org

主办单位：

www.diahome.org

名额有限，
报名从速！
在线注册

参会人员

- 临床医务人员
- 临床项目负责人
- 临床试验机构监查人员
- 医学事务负责人
- 法规事务人员
- 研发人员
- 卫生政策制定者

组委会主席

梁茂植　研究员
华西医院国家药品临床试验机构副主任兼I期临床试验研究室主任，临床药理研究室主任

华西医院国家药物临床试验机构/GCP中心负责人

组委会成员及讲者

Beat E. WIDLER　博士（主讲人）
欧洲临床质量保证和风险管理专家

李海燕　教授
北京大学第三医院药物临床试验机构主任

北京大学临床研究所副所长

刘海涛　医师
国际公共卫生学硕士
葛兰素史克（中国）投资有限公司全球质量合规部亚太地区临床发展质量保证部高级顾问

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association. Speakers and agenda are subject to change without notice. Recording of any DIA training material in any type of media, is prohibited without prior written consent from DIA.

第一天 | 4月9日 · 星期二

7:30 – 8:30 会议注册

8:30 – 8:45 欢迎致辞

8:45 – 9:45

促使赫尔辛基宣言以及ICH GCP出台的生物医学科研伦理历史

学习目的

通过本节的介绍，学员将了解：

- 药物研发和药剂产品使用过程中的灾难性事件（如：萨力多胺事件）。如何促进临床试验的伦理概念以及涉及上市后药用产品的伦理实施的发展。
- 个人的卫生保健与优先研究领域之间的利益冲突是什么。
- 赫尔辛基宣言如何致力于协助医务人员解决为患者提供最佳治疗和进行人体标准化研究之间所产生的冲突。
- 在临床试验中使用安慰剂的时机和方式及如何从伦理上得以恰当释义。
- 在临床试验的伦理行为中，ICH GCP，美国和欧盟立法有什么样的影响和重要意义。
- 在中国进行临床试验时，国际指南和法规具有什么样的相关性和重要性。

9:45 - 10:20 小组讨论

10:20 – 10:40 茶歇

10:40 – 11:30

临床I期到IV期，包括上市后的观察性试验中对受试者保护

学习目的

通过本节的介绍，学员将了解：

- 在不同类型的试验机构中，研究者和申办方对保护受试者应承担的责任是什么。
- 在涉及健康志愿者、住院病人与非住院病人的临床试验中需考虑哪些因素。
- 文化背景及医疗形式与伦理的相关性。
- 临床设计方案与临床试验伦理行为的相关性。
- 其它影响伦理的因素（技术和设备、药品管理、人员研讨等）。
- 有关责任、赔偿、保险以及数据保护和保密。
- 观察性研究中需关注哪些伦理方面的问题。
- 临床试验时所常见的伦理问题。

11:30 - 12:00 小组讨论

12:00 – 13:30 午餐

13:30 – 14:15

科研诚信，进行临床试验需要承担的伦理和社会责任以及出现差错时应当承担的道德责任

学习目的

通过本节的介绍，学员将了解：

- 临床试验中，研究者和申办方各应承担的社会责任和道德责任。
- 如何掌握患者临床数据的透明度。
- 如何处理临床研究中的严重质量问题。
- 发生争议与不良行为时所采取的措施。
- 如何妥善管理临床上出现的问题及确保研究的连续性。

14:15 - 14:30 小组讨论

14:30 - 15:00

确保可靠的受试者保护以及临床试验伦理行为的伦理审查过程

学习目的

通过本节的介绍，学员将了解：

- 伦理委员会进行伦理审查过程中的基本要素及其要求。
- 不同区域和国家伦理委员会对伦理问题解决的差异。

15:00 – 15:20 茶歇

15:20 – 16:15

小组练习：审查临床方案并识别其中的伦理问题

学习目的

案例研究将训练学员：

- 识别方案中容易出现的伦理问题。
- 识别试验中潜在的伦理挑战。
- 探索解决问题的策略。

16:15 – 17:00 小组讨论结果

17:00 第一天研讨结束

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association.

Speakers and agenda are subject to change without notice.

Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.

第二天 | 4月10日 • 星期三

8:30 – 9:15

临床试验中，健康成年受试者的知情同意过程

学习目的

通过本节的介绍，学员将了解：

- 口头知情同意和书面知情同意各自涉及的原则是什么。
- 知情同意书和患者信息表必备的构成要素有哪些。
- 知情同意书和患者信息表的功能和内容是什么。
- 如何把握知情同意过程中所获得的信息。临床研究者所应承担的责任。
- 当使用视频资料、小组会议等形式时应当考虑哪些因素。
- 如何与不同教育层次和有语言障碍的患者进行沟通以及如何处理沟通中可能发生的冲突。

9:15 - 10:00

小组练习：患者信息表和知情同意过程评议

学习目的

案例研究将训练学员：

- 识别知情同意书、患者信息表或给患者的材料中所常出现的伦理问题。
- 理解知情同意过程中存在的伦理挑战。
- 探索解决问题的策略。

10:00 – 10:30　小组讨论结果

10:30 – 10:50　茶歇

10:50 – 12:00

弱势人群临床试验中的伦理问题

学习目的

通过本节的介绍，学员将了解：

- 弱势人群的定义
- 临床试验中如何对待不同类型的弱势人群，比如无意识的、有智障的、存在严重精神问题的或已无有效治疗结果的患者。
- 儿童临床试验应考虑的因素及采取的预防措施。
- 对军人、学生、囚犯等人群的临床试验应考虑的因素及采取的预防措施。
- 对不符卫生保健标准的贫困地区进行临床试验时应考虑的因素及采取的预防措施。

12:00 – 12:30　小组讨论

12:30 – 13:45　午餐

13:45 – 14:30

分组练习：通过案例分析，学员讨论相关的伦理问题及解决方法

学习目的

案例研究将着重培养学员：

- 识别临床试验/临床项目中的道德风险以及潜在的危险。
- 风险评估。
- 降低或预防风险的措施。

14:30 – 14:45　小组讨论结果

14:45 - 15:15

临床试验中的诱导因素

学习目的

通过本节的介绍，学员将了解：

- 与GCP和伦理要求相悖的诱导。
- 对临床试验参试者的补偿。
- 广告内容。
- 对向研究者推荐病人的医生的补偿。
- 对健康志愿者的补偿及支付方式。
- 服务中心参与受试者招募有可能导致的伦理问题。
- 如何应对社会媒体。

15:30 – 16:00　小组讨论

16:00 – 16:30　茶歇

16:30 – 17:00

中国临床试验的伦理要求

学习目的

通过本节的介绍，学员将了解：

- 药物临床试验伦理审查制度的建立。
- 对伦理要求的理解。

17:00 – 17:30　小组讨论

17:30　研讨课程结束

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association.

Speakers and agenda are subject to change without notice.

Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.

TRAINING COURSE

Understanding and Implementing Best Ethics Practices in Clinical Research

April 9-10, 2013
Nanjing Hotel | Nanjing, China

This two-day course provides an in-depth, practical, and interactive forum so trainees can better understand the critical aspects of ethical requirements, appropriate patient protection, and the Informed Consent Process throughout clinical trials. Supported with examples of real-life experience, this course will deliver a comprehensive understanding of internationally accepted and requested ethical considerations in clinical trials, of an appropriate ethical review process, and the elements of a patient-adapted informed consent process. The trainer will also compare Chinese requirements and ICH/European/US requirements with special focus on ethical review, the informed consent process and issue management by providing practical cases.

SESSION AND ABSTRACT TOPICS

- The history of biomedical research ethics leading to the Declaration of Helsinki and ICH GCP
- Ethical requirements for clinical trials in China
- Patient protection in clinical trials from Phase 1 to Phase 4, including post marketing observational trials
- The ethical review process to ensure reliable patient protection and ethical conduct of clinical trials
- Identifying ethically critical aspects of a protocol provided for review
- The Informed Consent Process in trials with conscious, adult participants
- Critical review of a Patient Information Sheet and the informed consent process
- Ethical issues in clinical trials involving vulnerable adult populations and children
- Different case studies will be presented and the delegates will be asked to identify what the ethical issues are and how these can be addressed
- When support to and compensation of patients in clinical trials become an inducement
- Research integrity, ethics and social responsibility when conducting clinical trials and ethical responsibilities when things go wrong

LEARNING OBJECTIVES

At the end of the training course, participants should be able to:

- gain a better understanding of the ethics requirements and impacts in conducting clinical research
- have a better understanding of GCP, ICH and the SFDA new guideline for ethics
- follow the regulatory compliance effectively
- design good clinical studies with good ethics practices to ensure successful compliance inspections and regulatory submissions

For more information, contact:

Ying ZHAO
Tel. +86.10.6260.2242 | Fax: +86.10.6260.2201
email: dia@diachina.org

Fei XIE
Tel: +86.10.6260.2240 | Fax: +86.10.6260.2201
email: dia@diachina.org

Hosted by

Enrollment limited.

Register Early!

Online Register

WHO SHOULD ATTEND

- Medical professionals
- Clinical project managers, directors, group leaders
- Clinical trial/study site investigators
- Medical affairs professionals and medical directors
- Regulatory affairs professionals
- R&D scientists
- Public health policy makers

PROGRAM CHAIRPERSON

Maozhi LIANG, Professor
Director, Institute of Clinical Pharmacology, Lab. of Clinical Pharmacology and GCP Center of West China Hospital of Sichuan University, Chengdu, Sichuan, China

PROGRAM COMMITTEE & SPEAKERS

Beat E. WIDLER, PhD (Main Instructor)
Europe Clinical QA & Risk Management Expert, Switzerland

Haiyan LI, MD, Professor
Director, Drug Clinical Trial Center, Peking University Third Hospital
Vice Director, Peking University Clinical Research Institute, China

Haitao LIU, MD, Master of International Public Health
Senior Advisor, Clinical Development Quality Assurance Asia Pacific, Global Quality and Compliance, GlaxoSmithKline R&D, China

This training course is a part of the Clinical Research, Document and Records, Management, Good Cinical Practices & Quality Assurance, and Quality Risk Management Special Interest Areas.

DAY 1 | TUESDAY, APRIL 9

7:30 – 8:30 REGISTRATION

8:30 – 8:45 WELCOME AND INTRODUCTION

8:45 – 9:45

THE HISTORY OF BIOMEDICAL RESEARCH ETHICS LEADING TO THE DECLARATION OF HELSINKI AND ICH GCP

Learning Goal

At the end of this presentation participants will understand:

- How disasters in drug development and in the commercial use of pharmaceutical products and devices(e.g. thalidomide disaster)have shaped the development of ethical concepts for clinical trials and ethical behaviors once a medicinal product is commercialized.
- What the conflict of interest between individual health care and research priorities are.
- How the Declaration of Helsinki aims at helping physicians to overcome the conflict between providing best treatment to the individual patient versus performance of standardized research for the benefit of mankind.
- How and when the use of placebo in a clinical trial can morally and ethically be justified.
- What has been the impact and significance of ICH GCP, US and EU legislation on the ethical conduct of clinical trials.
- What the relevance and significance of international guidelines and rules are on the conduct of clinical trials in China.

9:45 - 10:20 GROUP DISCUSSION

10:20 – 10:40 COFFEE BREAK

10:40 – 11:30

PATIENT PROTECTION IN CLINICAL TRIALS FROM PHASE I TO PHASE IV, INCLUDING POST MARKETING OBSERVATIONAL TRIALS

Learning Goal

At the end of this presentation participants will understand:

- What the investigator's and sponsor's responsibility for optimal patient protection in different types of trial set-ups are
- What must be considered when a clinical trial is conducted in healthy volunteers' versus patients, hospitalized versus out-patients
- How cultural behaviors and the way medicine is practiced can impact on ethics.
- How a properly desinged, planned and implemented protocol determines the ethical conduct of a clinical trial.
- How technical and logistic aspects such as labeling/ reconstitution and administration of IMP(Investigationa Medicinal Product) adequate facilities, staffing and training of all those involved in a clinical trial impact ethics
- what one needs to know about liability indemnity and insurance as well as data protection and confidentiality.
- What ethical considerations are to be made when conducting observational studiers
- What are common pitfalls from an ethics perspective whe performing a clinical trial.

11:30 - 12:00 GROUP DISCUSSION

12:00 – 13:30 LUNCH BREAK

13:30 - 14:15

RESEARCH INTEGRITY, ETHICS AND SOCIAL RESPONSIBILITY WHEN CONDUCTING CLINICAL TRIALS AND ETHICAL RESPONSIBILITIES WHEN THINGS GO WRONG

Learning Goal

At the end of this presentation participants will understand:

- What the societal and morale responsibilities are of an investigator and sponsor when condcting a clinical trial.
- Transparency and disclosure and access to patient level data.
- How to act when serious quality issues occur.
- How to act when misconduct is suspected and confirmed.
- How to ensure adequate issue management and business continuity

14:15 - 14:30 GROUP DISCUSSION

14:30 – 15:00

THE ETHICAL REVIEW PROCESS TO ENSURE RELIABLE PATIENT PROTECTION AND ETHICAL CONDUCT OF CLINICAL TRIALS

Learning Goal

At the end of this presentation participants will understand:

- What the basic elements of the ethical review process by ethics committees and their requirements are.
- How approaches, conceps and processes of ethics committee organization and ethical review differ between regions and countries

15:00 - 15:20 COFFEE BREAK

15:20 – 16:15

EXERCISE: GROUP WORK TO IDENTIFY THE ETHICALLY CRITICAL ASPECTS IN A PROTOCOL PROVIDED FOR REVIEW

Learning Goal

The case study shall train participants in :

- Recognizing ethics pitfalls in a protocol.
- Identifying trial aspects that represent a possible ethics challenge
- Develop mitigating and preventive strategies.

16:15 – 17:00

COMMON REVIEW OF THE GROUP WORK FINDINGS

17:00 END OF DAY 1

DAY 2 | WEDNESDAY, APRIL 10

8:30 – 9:15

THE INFORMED CONSENT PROCESS IN TRIALS WITH CONSCIOUS, ADULT PARTICIPANTS

Learning Goal

At the end of this presentation participants will understand:

- What the principles of oral and written information to patients are.
- What the essential elements of a Informed Consent Form and Patient Information Sheet are.
- what the role and content of the Informed Consent Form and the Patient Information Sheet are.
- How the overall information and consent process should be handled and which tasks can or cannot be delegated by the investigator.
- What needs to be considered when using didactic tools such as videos, group meetings.
- How to deal with illiterate patients.
- How to deal with literate patients but who do not read and speak the local language.
- What the investigator's responsibilities and possible conflicts of interest in this process are.

9:15 – 10:00

EXERCISE: GROUP WORK: CRITICAL REVIEW OF A PATIEN INFORMATION SHEET AND THE INFORMED CONSENT PROCESS

Learning Goal

The case study shall train participants in:

- Recognizing ethics pitfalls in a Informed Consent Form and Patient Information Sheet as well as other material given to patients.
- Identifying ethics challenges in the consent process.
- Develop mitigating and preventive strategies.

10:00 - 10:30

COMMON REVIEW OF THE GROUP WORK FINDINGS

10:30 – 10:50 COFFEE BREAK

10:50 – 12:00

ETHICAL ISSUES IN CLINICAL TRIALS INVOLVING VULNERABLE POPULATIONS

Learning Goal

At the end of this presentation participants will understand:

- What vulnerable patients are.
- How to deal with different types of vulnerable patients such as patients who are unconscious when entered into a clinical trial, are mentally impaired, suffer from a severe psychiatric condition or have exhausted treatment options.
- What are the special conditions and precautions when conducting clinical trials in children.
- What are the special conditions and precautions when conducting or entering patients in a clinical trial who are in a dependent situation like soldiers, students, prisoners.
- What are the special conditions and precautions when conducting clinical trials in a geographical area where the health care system is substandard or where there is a prevalence of poverty.

12:00 - 12:30 GROUP DISCUSSION

12:30 – 13:45 LUNCH BREAK

13:45 – 14:30

EXERCISE: GROUP WORK : DIFFERENT CASE STUDIES ARE PRESENTED AND THE PARTICIPANTS ARE ASKED TO IDENTIFY WHAT THE ETHICAL ISSUES ARE AND HOW THESE CAN BE ADDRESSED

Learning Goal

At the end of this presentation participants will understand:

- Identifying ethics risks and pitfalls in a clinical trial/ a clinical program.
- Assessing the magnitude of risks identified
- Defining mitigating and preventive action.

14:30 – 14:45

COMMON REVIEW OF THE GROUP WORK FINDINGS

14:45 - 15:15

INDUCEMENT IN CLINICAL TRIALS

Learning Goal

At the end of this presentation participants will understand:

- What are inducements that are contrary to GCP and ethics.
- How clinical trial participants can be reimbursed for incurred costs such as travel expense, loss of income because of scheduled clinic visits.
- What can be stated in an advertisement
- What compensation, if any, can be given to another physician for referring patients to the investigator.
- How compensation should be paid to healthy volunteers becomes unethical
- What ethics risk could arise when a call center is involved in recruitment of randomization of patients
- How to deal with social media

15:15 - 15:45 GROUP DISCUSSION

15:45 – 16:00 COFFEE BREAK

16:00 – 17:00

ETHICAL REQUIREMENTS FOR CLINICAL TRIALS IN CHINA

Learning Goal

At the end of this presentation participants will understand:

- How in China the approach and thinking about ethics in clinical trials and commercialization of medicinal products has evolved and developed.
- What are the current ethical requirements in China.

17:00 - 17:30 GROUP DISCUSSION

17:30 END OF THE TRAINING COURSE

讲者介绍（ABOUT THE SPEAKERS）

Beat E. WIDLER 博士 （主讲人） 欧洲临床质量保证和风险管理专家

Dr. Widler is a biologist and obtained his Ph.D. in Microbiology from the Swiss Institute of Technology in Zurich, Switzerland, in 1982. He started his career in Pharma as a Drug Regulatory Affairs (DRA) manager. From 1986 to 2011 he was with Hoffmann-La Roche first as a DRA manager, then as clinical scientist and since 1993 in the International Clinical Quality Assurance depart ment that he led from 1997 to 2011. Dr. Widler operates now as an independent Clinical QA and Risk Management Expert and is Managing partner of Widler & Schiemann AG, Switzerland. Dr. Widler is ISO 9001 certified and a registered Lead Auditor with the International Register of Certified Auditors (IRCA). Since April 2001, he is also holder of the SwAPP (Swiss Association of Pharmaceutical Professionals) Diploma for Pharmaceutical Medicine.Dr. Widler is an active member in a variety of international GCP working parties (e.g., EFPIA, IFPMA, DIA, EFGCP) and currently serves on the DIA Board of Direcors and as chair of the DIA Advisory Committee Europe. Dr. Widler regularly lectures at DIA, WHO, ECPM (University Basel) seminars and training courses and is a member of the IMI Pharmatrain syllabus committee.

梁茂植 研究员（讲者）

华西医院国家药品临床试验机构副主任兼I期临床试验研究室主任；临床药理研究室主任；华西医院国家药物临床试验机构/GCP中心负责人

长期从事临床药理学和临床药动学科研及其教学工作，近年作为课题负责人完成了卫生行政部门与药品监督管理部门下达的1～5类新药Ⅰ期临床研究课题50余项。作为主研参加完成国家自然科学基金和省卫生厅基金课题5项，在研国家自然科学基金课题1项。承担和参加中华医学基金（CMB）课题（增进人类健康）1项，省中医药管理局课题1项，省卫生厅课题2项。发表核心期刊和/或统计源期刊学术论文100余篇，其中以第一作者和通讯作者发表论文33篇，18篇为SCI、Medline所收载。

在1991-2009年期间，曾先后前往美国伊利偌依州立大学研修临床药理学、参加菲律宾国立大学医学中心由WHO主办的“基本药物合理应用研讨班”、新加坡国立大学“临床实验室国际认可研讨班”、美国华盛顿州儿童医院“临床实验室CAP国际认可研讨班” 以及美国费城州立大学医学中心、美国国立卫生院等组织的新药研发和临床研究等专题的研讨研讨班。

李海燕 教授

心血管内科主任医师；北京大学第三医院药物临床试验机构主任；北京大学临床研究所副所长；北京大学生物医学伦理委员会副主任委员

临床专业：血管内科疾病，尤其是冠心病的介入性诊断和治疗，并对高血压病、高脂血症及心力衰竭的治疗和心血管内科危重急症的抢救工作积累了丰富的临床经验。曾在美国加州大学洛杉矶分校（UCLA）血管内超声中心实验室及心导管室做访问学者。期间发表4 篇SCI文章，其中2 篇发表在国际心血管权威杂志上。作为主要研究者及参与者完成药物临床试验30余项，涉及溶栓药、抗高血压药、调脂药、抗心力衰竭药、治疗冠心病药物等。参加国际多中心临床试验多项。完成的药物试验包括Ⅰ期-Ⅳ期。对药物临床试验的组织管理及实施有较丰富的经验。至今发表研究文章30余篇。2008年获国家科技重大专项《重大新药创制》GCP平台资助。

刘海涛 医师， 国际公共卫生学硕士

葛兰素史克（中国）投资有限公司 全球质量合规部亚太地区临床发展质量保证部高级顾问

自上海医科大学临床医学专业毕业后，于复旦大学附属中山医院从事临床工作。2003年赴澳洲学习，获悉尼大学国际公共卫生硕士学位后，开始介入药物临床研究工作，主要是为世界卫生组织热带疾病研究与研讨特别项目署（WHO/TDR）的临床项目担任临床监察与稽查工作。2006年作为访问学者赴美国西部伦理委员会（WIRB）学习。自2006年担任FERCAP(亚太地区伦理委员会论坛)医学官员，在亚太地区进行药物临床试验质量管理规范（GCP）与伦理审查研讨及伦理委员会评估工作。2009年至2010年就职于复旦大学附属华山医院，负责药物临床试验质量管理以及GCP和研究伦理研讨工作。2011就职于北京大学临床研究所，负责完善北京大学生物医学伦理委员会的建设，以及北京大学生物医学研究项目的伦理咨询工作和伦理相关的研讨项目。

2009年至2010年就职于复旦大学附属华山医院，负责药物临床试验质量管理以及GCP和研究伦理研讨工作。

第三届DIA中国伦理研讨：临床研究中最佳伦理规范的理解与实施

会议编码：#13980• 2013年4月9-10日
中国 • 南京

会议场所：
南京饭店
南京市中山北路259号（模范中路18号），邮编：210003
客房预订电话：（025）86826666 转70, 71
预订时间：8:30 -12:00 14:00-18:00

联系方式：
会议咨询：谢飞先生
中国 北京 海淀区中关村西区海淀东三街2号，欧美汇大厦七层766室，
邮编100080 电话: +86 10 6260 2240 传真: +86 10 6260 2201
E-mail: dia@diachina.org

取消注册：须在2013年3月26日前（含3月26日）

- 如需取消注册，须于规定日期前（含）以书面方式告知DIA中国办公室，在得到DIA中国办公室的书面确认后，方可视为取消成功。
- 凡已注册并付款者，若于规定之日前（含）取消注册，DIA中国办公室将办理退款手续，手续费人民币500元。
- 凡已注册并付款者，若逾期未办理取消手续，注册费将不予退还。
- 凡已注册并未付款者，且未联系DIA中国办公室，注册记录将自动取消
- 参会者应自行负责住宿、交通等有关预订及取消的相关费用。
- 会前未付款者，报名将被取消

请点击 在线注册
预了解更多DIA会议信息 可登录 www.diachina.org

注册费（加入DIA，点击此处 查询会员信息）

企业	会员价	非会员价（❑ 加入DIA，享受更多会员优惠和服务）
提前注册 (01月01日-03月26日)	RMB2300 ❑	RMB3100 ❑
标准价格 (03月27日-04月10日)	RMB2600 ❑	RMB3400 ❑
政府机构/学术机构	RMB1800 ❑	RMB2600 ❑

❑ 索取发票（如需发票，请填写以下信息）

❑ 增值税专用发票 ❑ 增值税普通发票

发票抬头 _____

发票金额 人民币 _____

服务项目 ❑咨询费 ❑会议费

收件人地址 _____

_____

收件人姓名 _____

联系电话 _____

*以下项目为增值税专用发票必填项目

企业纳税人识别号（即企业税务登记证号码）_____

银行帐号 _____

开户行 _____

地址 _____

联系方式 _____

团体注册优惠：同一公司5人同时注册，第6人免费参会！6人必须在同一时间注册并在会前付款才可享受该优惠。团体注册优惠不与其它优惠共用。

点击此处 填写团体注册表（第10页）

付款方式（汇率以当日外汇牌价为准）

❑ POS机刷卡

❑ 银行汇款

请即付人民币_____ 会议编码：13980

收 款 人： 迪亚恩（北京）医药信息咨询有限公司

开 户 行： 中国银行北京市朝阳支行营业部

银行帐号：333757195112

SWIFT Code: BKCH CN BJ 110

银行地址：北京市朝阳区东三环北路霞光里18号佳程广场A座一层

❑ 信用卡支付

持卡人姓名_____

发卡行_____ 信用卡有效期_____

卡号_____ 安全码_____

身份证号码 _____

❑ 维萨卡 ❑ 万事达卡

持卡人签名_____

* 请注意目前只接受下列信用卡：
境外信用卡： 维萨卡和万事达卡
境内信用卡：中国银行，中国建设银行，中国工商银行，广东发展银行，兴业银行

单位类别 ❑ 制药企业 ❑ 政府部门 ❑ 学术单位 ❑ 外包服务研究机构/CRO

请填写下表并保持字迹清晰

姓 _____ 名 _____ 职位 _____ 称谓：❑先生 ❑女士 ❑教授 ❑博士/医师

单位（公司）名称（英文）_____

中文地址（请注明地址以便邮寄）_____

英文地址 _____

省份及城市_____ 国家 _____ 邮政编码 _____ ❑ 公司地址 ❑ 家庭地址

电话 _____ 传真 _____ 手机（必填）_____

电子邮箱（必填，以便通过电子邮件发送确认）_____

如果您传真或邮寄报名表，请提供您的名片或名片复印件

Understanding and Implementing Best Ethics Practices in Clinical Research Training Course

Event I.D. # 13980 – April 9-10, 2013

Nanjing, China

HOTEL INFORMATION
Nanjing Hotel
No. 259 Zhong Shan Beilu, NO. 18 Mo Fan Zhonglu Nanjing, Jiangsu, China
Hotel Reservation Tel. (025) 86826666 ext. 70, 71
Reservation Hr. 8:30 – 12:00 14:00 – 18:00

DIA CHINA OFFICE
7/F, Room 766, Metropolis Tower, No.2 Haidian East Third Street, Zhongguancun Xi Zone, Haidian District, Beijing, 100080, China
Tel: +86.10.6260.2240; Fax: +86.10.6260.2201
email: Fei.Xie@diachina.org or DIA@diachina.org
web: www.diachina.org

CANCELLATION POLICY: ON OR BEFORE MARCH 26, 2013
Cancellation must be made in writing and received by March 26, 2013, for full refund.

- A cancellation processing fee of RMB 500.00 will be deducted from the refund for each paid registrant.
- No refund if the written cancellation is received after March 26, 2013
- Registrant will be responsible for own travel and hotel reservation and expenses
- If payment is not received by the due date, the registration is considered cancelled

Please click here for online Register
For more meeting details Please visit www.diachina.org

REGISTRATION FEES (Click Here to Check Your Membership Status)

INDUSTRY	MEMBER	NON-MEMBER (❑ Join DIA for More Member Benefits)	
Early-bird (Jan. 01 - Mar. 26)		RMB2300 ❑	RMB3100 ❑
Standard (Mar. 27 - Apr. 10)		RMB2600 ❑	RMB3400 ❑
NONPROFIT/ACADEMIA/GOVERNMENT	RMB1800 ❑	RMB2600 ❑	

REQUEST CHINESE OFFICIAL INVOICE (FAPIAO)

❑ Yes ❑ No

Fapiao Title _____

Amount (RMB) _____

Service Item ❑ Meeting Fee ❑ Training Fee

Recipient Address _____

_____

Recipient _____

Phone _____

GROUP DISCOUNTS* Register 5 and receive a complimentary registration for the 6th! **All 6 individuals must register and prepay prior to the event – no exceptions. Group registration does not apply to the already-discounted fees for government or charitable nonprofit/academia.**

* Click here or go to page 10 to complete the Group Registration Form

** The confirmation letter will be sent to the registered participants one week prior to the event.

PAYMENT

* Payment in other currencies will be based on the financial institution's exchange rate.

❑ POS Machine

❑ Bank Transfer

Payment in the amount of RMB_____ ID: 13980

Payee: DIA (Beijing) Healthcare Information Consulting Limited

Bank Name: Bank of China, Beijing Chaoyang Sub-branch Banking Dept.

Bank Account: 333757195112

SWIFT Code: BKCH CN BJ 110

Bank Address: 1st Floor, Tower A, Gateway, No.18 Xiaguangli, North Road, East Third Ring, Chaoyang District, Beijing, 100027, P.R.China

❑ CREDIT CARD

Cardholder Name _____

Card Issue Bank_____ Exp. Date (mm/yyyy)_____

Card #_____ Security Code_____

ID # _____

❑ Visa ❑ Master Card Signature_____

* Only following cards are accepted:
Foreign Credit Card: VISA & Master Card.
Domestic Credit Card: Bank of China, China Construction Bank, Industrial and Commercial Bank of China, Guangdong Development Bank, and China Industrial Bank.

Please check the applicable category: ❑ Industry ❑ Government ❑ Academia ❑ CSO/CRO

PLEASE PRINT ALL INFORMATION CLEARLY

Last Name First Name M.I. Full Name in Chinese (If applicable) Please check one: ❑ Mr. ❑ Ms. ❑ Prof. ❑ Dr.

Job Position Affiliation (Company) ❑ Business Address ❑ Home Address

Address (Please write your address in the format required for delivery to your country.) City Postal Country/Region

Address in Chinese (If applicable)

Telephone Number Fax Number Mobile Number (Required)

Email (Required for confirmation)

IF FAXING OR MAILING THIS FORM, PLEASE PROVIDE A COPY OF REGISTRANT'S BUSINESS CARD.

Group Registration Form 团体注册表

Understanding and Implementing Best Ethics Practices in Clinical Research Training Course– April 9-10, 2013
Nanjing, China

团体注册优惠（仅限企业用户）
同一公司5人同时注册，第6人免费参会！6人必须在同一时间注册并在会前付款才可享受该优惠。团体注册优惠不与其它优惠共用。

GROUP DISCOUNTS (ONLY FOR INDUSTRY ATTENDEES)
Register 5 and receive a complimentary registration for the 6th! All 6 individuals must register and prepay prior to the event – no exceptions. Group registration does not apply to the already-discounted fees for government or charitable nonprofit/academia.

公司名称（Company Name）_____

中文地址（Chinese Address）_____

英文地址 (English Address）_____

省份(Province)_____ 国家 (Country/Region)_____ 邮政编码(Postal) _____

（1） 注册费（Registration Fee）：_____

姓 (Last Name) _____ 名 (First Name)_____ 职位 (Title) _____

中文名（Chinese Name) _____ 称谓: ❑先生(Mr.) ❑女士(Ms.) ❑教授(Prof.) ❑博士/医师(Dr.)

电话(Tel) _____ 传真(Fax) _____ 手机（Mobile）_____

电子邮箱（email）_____

（2） 注册费（Registration Fee）：_____

姓 (Last Name) _____ 名 (First Name)_____ 职位 (Title) _____

中文名（Chinese Name) _____ 称谓: ❑先生(Mr.) ❑女士(Ms.) ❑教授(Prof.) ❑博士/医师(Dr.)

电话(Tel) _____ 传真(Fax) _____ 手机（Mobile）_____

电子邮箱（email）_____

（3） 注册费（Registration Fee）：_____

姓 (Last Name) _____ 名 (First Name)_____ 职位 (Title) _____

中文名（Chinese Name) _____ 称谓: ❑先生(Mr.) ❑女士(Ms.) ❑教授(Prof.) ❑博士/医师(Dr.)

电话(Tel) _____ 传真(Fax) _____ 手机（Mobile）_____

电子邮箱（email）_____

（4） 注册费（Registration Fee）：_____

姓 (Last Name) _____ 名 (First Name)_____ 职位 (Title) _____

中文名（Chinese Name) _____ 称谓: ❑先生(Mr.) ❑女士(Ms.) ❑教授(Prof.) ❑博士/医师(Dr.)

电话(Tel) _____ 传真(Fax) _____ 手机（Mobile）_____

电子邮箱（email）_____

（5） 注册费（Registration Fee）：_____

姓 (Last Name) _____ 名 (First Name)_____ 职位 (Title) _____

中文名（Chinese Name) _____ 称谓: ❑先生(Mr.) ❑女士(Ms.) ❑教授(Prof.) ❑博士/医师(Dr.)

电话(Tel) _____ 传真(Fax) _____ 手机（Mobile）_____

电子邮箱（email）_____

（6） 请将免费参会人信息填写在下列表格中 (Pleasse complete following personal information for complimentary discount）

姓 (Last Name) _____ 名 (First Name)_____ 职位 (Title) _____

中文名（Chinese Name) _____ 称谓: ❑先生(Mr.) ❑女士(Ms.) ❑教授(Prof.) ❑博士/医师(Dr.)

电话(Tel) _____ 传真(Fax) _____ 手机（Mobile）_____

电子邮箱（email）_____